May. 13 at 8:26 PM
$AZTA Azenta, Form Bio announce strategic partnership
Azenta announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence life sciences technology company, to enhance adeno-associated virus gene therapy development through a fully integrated sequencing and data analysis solution. This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy with Form Bio's AI- and machine learning-powered analysis pipelines.
The integration of these capabilities aims to provide gene therapy developers with data-driven insights into AAV capsid contents, improving safety, efficacy, and manufacturability. GENEWIZ will provide synthesis and packaging of transgene expression cassettes, complemented by high-quality, long-read sequencing services for AAV gene therapy.
Form Bio will conduct comprehensive AAV Genome Integrity Characterization using Long-read AAV Analysis (LAAVA) software, identifying key opportunities to enhance vector integrity and safety, while providing actionable insights through detailed reporting. This combination enables a streamlined process that integrates sequencing, vector design, and development workflows, ultimately reducing time and cost to reach lead candidates, accelerating the path to market for innovative therapies.
